Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Gilead Sciences Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Accounts payable 1.66 1.00 1.10 0.89 0.94 1.00 1.01 1.43 0.98 0.90 0.92 1.04 0.87 0.89 0.84 1.23 0.87 0.95 0.99 1.16 1.07 0.98 0.92
Accrued rebates 7.54 7.32 7.57 6.12 5.95 5.61 5.62 5.51 5.87 5.60 5.47 4.77 5.02 4.84 4.99 5.06 5.49 5.97 5.79 5.64 6.17 5.67 6.32
Current portion of long-term debt and other obligations, net 3.32 3.38 6.51 2.89 2.87 6.48 3.69 3.60 3.63 1.62 1.62 2.23 3.74 3.33 3.35 4.03 2.46 5.36 3.35 4.06 4.22 3.16 3.98
Other current liabilities 8.98 8.42 7.93 8.26 9.38 9.32 6.69 7.25 6.18 6.55 5.55 9.04 5.64 5.96 5.20 6.34 6.80 6.61 4.74 4.99 4.71 4.37 3.74
Current liabilities 21.50% 20.12% 23.12% 18.16% 19.15% 22.40% 17.01% 17.79% 16.66% 14.67% 13.57% 17.09% 15.27% 15.02% 14.38% 16.66% 15.62% 18.89% 14.86% 15.84% 16.18% 14.18% 14.95%
Long-term debt, net, excluding current portion 39.32 40.20 38.24 37.33 37.18 34.02 37.10 36.34 36.69 40.07 39.92 37.05 37.52 41.06 41.35 41.87 45.65 37.73 36.99 35.85 37.35 38.10 38.32
Long-term income taxes payable 1.43 1.38 3.49 3.28 3.35 4.19 6.10 6.20 6.37 6.18 7.60 7.02 6.92 6.76 7.44 7.33 8.25 9.13 9.37 9.92 9.89 9.23 9.24
Deferred tax liability 1.46 1.69 1.66 2.56 3.18 3.38 3.88 4.23 4.85 5.35 5.84 6.41 6.86 6.43 6.61 5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other long-term obligations 2.56 2.64 2.48 2.06 1.48 2.17 2.06 1.87 1.77 1.57 1.50 1.44 1.43 1.73 2.12 1.77 1.78 1.82 1.66 1.64 1.52 2.49 2.32
Long-term liabilities 44.77% 45.92% 45.87% 45.22% 45.19% 43.76% 49.15% 48.64% 49.68% 53.18% 54.86% 51.92% 52.73% 55.98% 57.52% 56.70% 55.68% 48.68% 48.01% 47.41% 48.77% 49.83% 49.89%
Total liabilities 66.27% 66.04% 68.99% 63.38% 64.34% 66.16% 66.16% 66.43% 66.34% 67.85% 68.43% 69.00% 68.00% 71.01% 71.90% 73.36% 71.30% 67.57% 62.87% 63.25% 64.94% 64.01% 64.84%
Preferred stock, par value $0.001 per share; none outstanding 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, par value $0.001 per share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Additional paid-in capital 13.44 13.11 12.10 10.46 10.07 9.64 9.36 8.79 8.35 8.00 7.72 6.86 6.69 6.28 6.06 5.67 6.10 6.28 5.54 4.95 4.85 4.25 3.97
Accumulated other comprehensive income (loss) 0.13 0.17 0.12 0.05 0.05 0.02 -0.03 0.00 0.16 0.14 0.12 0.12 0.11 0.06 0.06 -0.09 0.04 0.13 0.08 0.14 0.20 0.16 0.21
Retained earnings 20.31 20.84 18.93 26.24 25.66 24.29 24.60 24.83 25.19 24.04 23.76 24.02 25.19 22.64 21.96 21.02 22.52 25.83 31.32 31.46 29.78 31.37 30.76
Total Gilead stockholders’ equity 33.88% 34.12% 31.16% 36.75% 35.78% 33.94% 33.93% 33.62% 33.70% 32.19% 31.59% 31.01% 32.00% 28.98% 28.08% 26.61% 28.66% 32.23% 36.94% 36.55% 34.84% 35.78% 34.93%
Noncontrolling interest -0.16 -0.16 -0.15 -0.14 -0.12 -0.10 -0.09 -0.05 -0.04 -0.03 -0.02 -0.01 0.00 0.01 0.02 0.03 0.04 0.21 0.19 0.20 0.22 0.21 0.22
Total stockholders’ equity 33.73% 33.96% 31.01% 36.62% 35.66% 33.84% 33.84% 33.57% 33.66% 32.15% 31.57% 31.00% 32.00% 28.99% 28.10% 26.64% 28.70% 32.43% 37.13% 36.75% 35.06% 35.99% 35.16%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Gilead Sciences Inc. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q1 2024 to Q2 2024 but then slightly increased from Q2 2024 to Q3 2024.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Gilead Sciences Inc. long-term liabilities as a percentage of total liabilities and stockholders’ equity increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Gilead Sciences Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q1 2024 to Q2 2024 but then slightly increased from Q2 2024 to Q3 2024.
Total Gilead stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Gilead Sciences Inc. total Gilead stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.